For individuals with familial hypercholesterolemia (FH) who face elevated ASCVD risks due to high cholesterol levels, anti-PCSK9 monoclonal antibodies have been in use since 2015 in Belgium. This evidence concerns the gene PCSK9 and familial hyperaldosteronism.